FTC Fights Watson's Bid To Block Lidoderm Antitrust Suit
By Adam Rhodes ( June 8, 2017, 6:55 PM EDT) -- The Federal Trade Commission renewed its opposition Wednesday to Watson Laboratories' bid for a ruling that the agency lacks the authority to pursue a pay-for-delay suit against it over pain relief patch Lidoderm, telling a Pennsylvania federal court that the drugmaker's legal interpretation would keep the FTC from challenging assorted large-scale frauds....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.